Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(1059/week)
    • Manufacturing(521/week)
    • Energy(395/week)
    • Technology(992/week)
    • Other Manufacturing(316/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Sintilimab

Aug 12, 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT® (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Jun 21, 2020
Innovent Announces The Stock Exchange of Hong Kong Limited Approved the "B" Marker Removal from the Company's Stock Symbol in the HKEX
Jun 19, 2020
Innovent Announces the NMPA Granted Marketing Approval for BYVASDA® (Bevacizumab Biosimilar) in China
Jun 02, 2020
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
Jun 01, 2020
Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study
May 31, 2020
Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma
May 31, 2020
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 31, 2020
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma
May 31, 2020
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
May 25, 2020
Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China
May 18, 2020
Innovent Biologics and MD Anderson Announce a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT® (Sintilimab Injection) in Rare Cancers
May 14, 2020
Innovent Announces Key Results from a Number of Clinical Studies to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
May 13, 2020
TYVYT® (Sintilimab Injection) ORIENT-2 Study Met its Primary Endpoint of Overall Survival in the Second-Line Treatment of Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Apr 27, 2020
Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China
Apr 23, 2020
Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum as First-Line Therapy in Non-squamous NSCLC
Mar 30, 2020
Innovent Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Progress
Mar 25, 2020
Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China
Jan 12, 2020
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
Jan 07, 2020
Sirnaomics and Innovent Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining STP705 and Sintilimab in the US
Jan 07, 2020
Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US
  •  
  • Page 1
  • ››

Latest News

Jul 12, 2025

Gravity Launches How to Train Your Dragon Collaboration for Ragnarok Online

Jul 12, 2025

Pomerantz Law Firm Announces the Filing of a Class Action Against Apple Inc. and Certain Officers - AAPL...

Jul 12, 2025

CGTN: Bridging dialogue: China promotes integration, mutual learning among civilizations

Jul 12, 2025

Boeing evades MAX crash trial with last-minute settlement

Jul 12, 2025

Sensient Announces Conference Call

Jul 12, 2025

Silgan to Release Second Quarter 2025 Earnings Results on July 30, 2025

Jul 12, 2025

Mesabi Trust Press Release

Jul 12, 2025

Fastenal Company Announces Cash Dividend

View all News

Agenda

30
September
PortugalTroia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia